Great Point Partners as of Sept. 30, 2018
Portfolio Holdings for Great Point Partners
Great Point Partners holds 30 positions in its portfolio as reported in the September 2018 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| BioCryst Pharmaceuticals (BCRX) | 9.5 | $61M | 8.0M | 7.63 | |
| Acceleron Pharma | 8.2 | $53M | 918k | 57.23 | |
| Zafgen | 6.2 | $40M | 3.4M | 11.69 | |
| Iovance Biotherapeutics (IOVA) | 6.1 | $39M | 3.5M | 11.25 | |
| United Therapeutics Corporation (UTHR) | 6.0 | $38M | 300k | 127.88 | |
| Kura Oncology (KURA) | 5.8 | $37M | 2.1M | 17.50 | |
| Exelixis (EXEL) | 5.7 | $37M | 2.1M | 17.72 | |
| Ptc Therapeutics I (PTCT) | 5.3 | $34M | 718k | 47.00 | |
| Endocyte | 4.5 | $29M | 1.6M | 17.76 | |
| Voyager Therapeutics (VYGR) | 4.1 | $27M | 1.4M | 18.92 | |
| Alnylam Pharmaceuticals (ALNY) | 4.1 | $26M | 300k | 87.52 | |
| Savara (SVRA) | 3.9 | $25M | 2.2M | 11.16 | |
| ACADIA Pharmaceuticals (ACAD) | 3.9 | $25M | 1.2M | 20.76 | |
| Foamix Pharmaceuticals | 3.6 | $23M | 4.0M | 5.73 | |
| Five Prime Therapeutics | 3.6 | $23M | 1.6M | 13.92 | |
| Cytokinetics (CYTK) | 3.4 | $22M | 2.2M | 9.85 | |
| Spark Therapeutics | 3.3 | $21M | 393k | 54.55 | |
| Enanta Pharmaceuticals (ENTA) | 2.8 | $18M | 210k | 85.46 | |
| Menlo Therapeutics | 2.0 | $13M | 1.3M | 9.85 | |
| Tg Therapeutics (TGTX) | 1.7 | $11M | 2.0M | 5.60 | |
| Protagonist Therapeutics (PTGX) | 1.6 | $10M | 982k | 10.29 | |
| Argenx Se (ARGX) | 1.5 | $9.8M | 129k | 75.84 | |
| Madrigal Pharmaceuticals (MDGL) | 1.4 | $8.7M | 40k | 214.13 | |
| Intra Cellular Therapies (ITCI) | 0.7 | $4.3M | 200k | 21.70 | |
| Zymeworks | 0.6 | $3.8M | 242k | 15.70 | |
| Sunesis Pharmaceuticals Inc Ne | 0.3 | $2.0M | 1.0M | 2.00 | |
| Acer Therapeutics | 0.3 | $1.8M | 59k | 30.84 | |
| Sierra Oncology | 0.1 | $834k | 491k | 1.70 | |
| Streamline Health Solutions (STRM) | 0.0 | $154k | 130k | 1.18 | |
| Cti Biopharma | 0.0 | $46k | 21k | 2.15 |
